Cytox in Collaboration with AKESOgen Extends Genetic Test for Assessing Alzheimer’s Disease Risk to Include Saliva Samples

Cytox Ltd

 

Cytox in Collaboration with AKESOgen Extends Genetic Test for Assessing Alzheimer’s Disease Risk to Include Saliva Samples


Pioneering polygenic risk scoring approach verified for banked DNA, blood and saliva samples

 

8th May 2018: Oxford & Manchester, UK and Atlanta, GA.  Cytox, a precision medicine testing company which today is commercializing polygenic risk scoring (PRS) and other approaches for assessing genetic risk for developing Alzheimer’s disease, has collaborated with integrated genomics and genetics leader AKESOgen to verify the performance of the Cytox genoBAR™ test with saliva samples.

 

The Cytox genoBAR research test is intended to help pharma, biotech, and sponsors of large cohort studies reduce the time and high cost associated with identifying and stratifying subjects for clinical trials and large-population research, which can take more than six months and run tens of thousands of dollars per participant. The work performed by Cytox and AKESOgen resulted in over 99% concordance between the SNPs used in the PRS identified from blood and saliva samples collected from the same subjects and run on the Cytox variaTECT™ microarray on the Applied Biosystems™ GeneTitan™ Multi-Channel (MC) instrument platform from Thermo Fisher Scientific. The saliva samples were collected using the DNA Genotek DNA saliva collection kit. The results of this verification study will provide an additional means to collect DNA from prospective clinical trial and cohort subjects and opens the possibility of screening even larger population groups for disease risk.

 

“The extension of our test to include saliva samples in addition to blood samples and biobanked DNA represents a significant step forward,” commented Dr Richard Pither, CEO of Cytox, “Our customers in pharma and biotech now have the ability to collect larger numbers of samples in a highly efficient and non-invasive way, opening the doors to the cost-effective screening of tens to hundreds of thousands of prospective clinical study participants, or still larger population networks associated with regional healthcare centres or national dementia programmes.”

 

Dr Mark Bouzyk, Chief Scientific Officer at AKESOgen, added, “The collaboration between AKESOgen and Cytox aims to ensure the highest accuracy possible across all the biological samples types generally used for genetic analysis. We believe these results and our partnership with Cytox will eventually result in more effective screening and diagnosis for those patients impacted by Alzheimer’s disease.”

 

-ends-

 

About Cytox

Cytox Group Limited is a precision medicine information company whose mission is to transform how treatments are developed, people are screened and therapies are prescribed for the most prevalent neurological diseases, including Alzheimer’s disease. Alzheimer’s disease today impacts over 46 million people globally, reaching 74.7 million in 2030 and projected to grow to over 131 million people by 2050 with an economic impact to exceed two trillion dollars. Leveraging the proprietary Cytox variaTECT™ SNP genotyping array, Cytox SNPfitR™ algorithm for polygenic risk scoring and running on the proven power and scalability of the Applied Biosystems™ GeneTitan™ Multi-Channel (MC) Instrument platform, the company offers genomic profiling testing assays and services to early access collaborators in academia and Biopharma pursuing clinical research and drug development. The service is designed to help researchers and clinicians access the biology and genetics behind dementia, stratify patients to enable more cost effective and information rich clinical trials, and ultimately establish risk for cognitive decline and matching with the most appropriate targeted therapy.

 

The company is headquartered in the United Kingdom with assays and services available to early access collaborators globally. For more information, please visit www.cytoxgroup.com and follow the company on Twitter at @CytoxDx and on LinkedIn. Cytox’s assay and testing services are for research use only and not for use in diagnostic procedures.

 

About AKESOgen

AKESOgen is an integrated Clinical Laboratory Improvement Amendments (CLIA) compliant and College of American Pathology (CAP) accredited genomics, genetics and bio-banking company that services the pharmaceutical, biotechnology, clinical, academic, and government sectors for clinical trials, diagnostic clinical testing, and research. Based in Atlanta, GA, USA, the company’s main focus is oncology, neurology and personalized medicine. AKESOgen’s services include providing high-throughput, biomarker profiling, cytogenetic arrays, sequencing, and genomics analysis utilizing different types of markers (e.g. DNA, mRNA, miRNA, and methylation). For more information, visit www.akesogen.com.

 

 

Contact:

Cytox Limited

Richard Pither, CEO

+44(0) 1865 338018

richard.pither@cytoxgroup.com

www.cytoxgroup.com

 

AKESOgen

Mark Bouzyk, CSO

+1 770 542 0890

mbouzyk@akesogen.com

www.akesogen.com

 

Share this Facebooktwittergoogle_plusredditlinkedinmailFacebooktwittergoogle_plusredditlinkedinmail

AKESOgen recognized as Georgia Small Business Rock Star of 2018

Georgia Economic Development Association

 

AKESOgen recognized as Georgia Small Business Rock Star

 

ATLANTA – March 19, 2018—AKESOgen was recognized by the state of Georgia as a Small Business Rock Star today at a luncheon hosted by the Georgia Department of Economic Development (GDEcD) and the Georgia Economic Developers Association (GEDA).

 

“What an honor it is to celebrate Georgia’s Small Business Rock Stars during the state’s annual Small Business Week,” said Commissioner Pat Wilson. “Anytime that we can put a spotlight on Georgia’s small businesses is a win-win for the state. These companies keep our economy thriving, and help Georgia maintain its status as the No.1 state in the nation in which to do business.”

 

Genetics and understanding your own genetic make up (DNA) is becoming pervasive in society. i.e. what makes you who you are. We are applying these new genetic technologies in fields such as cancer and Alzheimer’s as well as consumer genomics.” said Dr. Mark Bouzyk, Chief Scientific Officer at AKESOgen. “We are offering new precision medicine testing to understand outcomes and help identify which medicines make sense for the patient. In order for us to have grown this critical business we are deeply indebted to the outstanding support of GDEcD, Partnership Gwinnett, Georgia’s Innovation Crescent, the Georgia Research Alliance and GeorgiaBIO”.

 

This year’s Small Business Rock Stars winners include: AKESOgen, Inc. from Gwinnett County; STRAND Clinical Technologies from Columbia County; Gottwals Books from Peach County and SouthLife Supply Co. from Thomas County.

 

“With almost 98 percent of Georgia companies employing fewer than 100 people, small business has a tremendous impact on Georgia’s economy,” said GDEcD Director of Entrepreneur & Small Business Mary Ellen McClanahan. “The Rock Star recognition provides the perfect opportunity to showcase how important small businesses are to the state and of course, the local economy.”

 

These companies have shown increases in revenue, sales, exporting, product lines, jobs and economic impact. Additionally, the Small Business Rock Stars have shown dedication to their entrepreneurial spirit, creativity and a unique approach to conducting business to take them to the next level.

 

Governor Nathan Deal declared March 19-23 as Georgia Small Business Week to celebrate the achievements made my small businesses throughout the state.

 

“GEDA supports all types of economic development where jobs and investment are created, and where the quality of life is improved for our citizens,” said GEDA President Kevin Shea. “We are proud to support small businesses of all sizes through our members and their organizations all over the State of Georgia. Congratulations to this year’s award-winning small businesses.”

 

 

The Georgia Department of Economic Development’s small business efforts and outreach are directed by GDEcD Director of Entrepreneur & Small Business Mary Ellen McClanahan.  To access more information about these programs and more visit www.georgia.org/rockstars and www.georgia.org/smallbusinessweek.

 

###

 

About the Georgia Department of Economic Development

The Georgia Department of Economic Development (GDEcD) plans, manages and mobilizes state resources to attract new business investment to Georgia, drive the expansion of existing industry and small business, locate new markets for Georgia products, inspire tourists to visit Georgia and promote the state as a top destination for arts events and film, music and digital entertainment projects.

 

About GEDA

Celebrating 51 years of service excellence, the Georgia Economic Developers Association is the leading professional organization advancing Georgia’s economic vitality. GEDA is a non-profit association of professionals, volunteers and supporters. The association provides networking and professional development opportunities for its members, and supports public policies that promote quality job creation and sustainable economic development throughout the state. For more information, visit www.geda.org

 

About AKESOgen, Inc.

AKESOgen is an integrated Clinical Laboratory Improvement Amendments (CLIA) compliant and College of American Pathology (CAP) accredited genomics, genetics and bio-banking company that services the pharmaceutical, biotechnology, clinical, academic, and government sectors for clinical trials, diagnostic clinical testing, and research. Based in Atlanta, GA, USA, the company’s main focus is oncology, neurology and personalized medicine. AKESOgen’s services include providing high-throughput, biomarker profiling, cytogenetic arrays, sequencing, and genomics analysis utilizing different types of markers (e.g. DNA, mRNA, miRNA, and methylation). For more information, visit www.akesogen.com.

Share this Facebooktwittergoogle_plusredditlinkedinmailFacebooktwittergoogle_plusredditlinkedinmail